Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver

Danish Medical Bulletin

Volumn 44, Issue 2, 1997, Pages 191-207

  Jespersen, Bente ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE;

DIURESIS; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; NEPHROTIC SYNDROME; REVIEW; SODIUM EXCRETION; SODIUM RETENTION; WATER RETENTION;

BODY WATER; GLOMERULAR FILTRATION RATE; HUMANS; LITHIUM; LIVER CIRRHOSIS; METABOLIC CLEARANCE RATE; NATRIURESIS; NEPHROTIC SYNDROME; RENAL CIRCULATION;

EID: 0030998913     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (237)

1. Jespersen B, Danielsen H, Pedersen EB. Atrial natriuretic peptide and blood volume in patients with chronic glomerulonephritis: Effects of albumin and frusemide administration. Nephrology Dialysis Transplantation 1990; 5: 997-1006.
2. 2 and blood volume in the nephrotic syndrome. Nephrology Dialysis Transplantation 1991; 6: 402-409.
3. Jespersen B, Eiskjær H, Pedersen EB. Effect of atrial natriuretic peptide on blood pressure, guanosine 3′:5′-cyclic monophosphate release and blood volume in uraemic patients. Clinical Science 1990; 78: 67-73.
4. Jespersen B, Eiskjær H, Mogensen CE, Sørensen SS, Pedersen EB. Reduced natriuretic effect of atrial natriuretic peptide in nephrotic syndrome: A possible role of decreased cyclic guanosine monophosphate. Nephron 1995; 71: 44-53.
5. 2 excretion, plasma arginine vasopressin and renal water excretion after oral water loading in early hepatic cirrhosis. European Journal of Clinical Investigation 1988; 18: 202-206.
6. 2 in liver cirrhosis: relation to blood volume and changes in blood volume after furosemide. European Journal of Clinical Investigation 1990; 20: 632-641.
7. Jespersen B, Eiskjær H, Jensen JD, Mogensen CE, Sørensen SS, Pedersen EB. Effects of high dose atrial natriuretic peptide on renal haemodynamics, sodium handling and hormones in cirrhotic patients with and without ascites. Scandinavian Journal of Clinical and Laboratory Investigation 1995; 55: 273-288.
8. Abraham WT, Schrier RW. Body fluid volume regulation in health and disease. Advances in Internal Medicine 1994; 39: 23-47.
9. Firth JD, Ledingham JGG. Renal sodium retention in the nephrotic syndrome. Aust NZ J Med 1991; 21: 893-901.
10. Arroyo V, Ginès P. Mechanism of sodium retention and ascites formation in cirrhosis. J Hepatol 1993; 17(Suppl.2): S24-S28.
11. Humphreys MH. Mechanisms and management of nephrotic edema. Kidney Int 1994; 45: 266-281.
12. Thomassen A, Bagger JP, Nielsen TT, Pedersen EB. Atrial natriuretic peptide during pacing in controls and patients with coronary artery disease. Int J Cardiol 1987; 17: 267-276.
13. Awazu M, Ichikawa I. Biological significance of atrial natriuretic peptide in the kidney. Nephron 1993; 63: 1-14.
14. Blaine EH. Atrial natriuretic factor plays a significant role in body fluid homeostasis. Hypertension 1990; 15: 2-8.
15. Jamison RL, Canaan-Kühl S, Pratt R. The natriuretic peptides and their receptors. Am J Kidney Dis 1992; 20: 519-530.
16. Ardaillou R, Dussaule J-C. Role of atrial natriuretic peptide in the control of sodium balance in chronic renal failure. Nephron 1994; 66: 249-257.
17. Hollister AS, Rodeheffer RJ, White FJ, Potts JR, Imada T, Inagami T. Clearance of atrial natriuretic factor by lung, liver and kidney in human subjects and the dog. J Clin Invest 1989; 83: 623-628.
18. Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacological reviews 1987; 39: 163-196.
19. Grandes S, Gallego MJ, Riesco A, Farré L, Millas I, Casado S, Hernando L, Caramelo C. Mechanisms of renal effects of different agents stimulating production of cGMP. Am J Physiol 1991; 261: H1109-H1114.
20. Sagnella GA, Markandu ND, Buckley MG, Singer DRJ. Atrial natriuretic peptide-cyclic GMP relationships in normal humans: effects of dietary sodium intake. Clin Sci 1993; 85: 13-17.
21. Wong KR, Xie M-H, Shi L-B, Liu F-Y, Huang C-L, Gardner DG, Cogan MG. Urinary cGMP as biological marker of the renal activity of atrial natriuretic factor. Am J Physiol 1988; 255: F1220-F1224.
22. Heim J-M, Gottmann K, Weil J, Haufe MC, Gerzer R. Is cyclic GMP a clinical useful marker for ANF action? Z Kardiol 1988; 77 (Suppl 2): 41-46.
23. Broadus AE, Kaminsky NI, Hardman JG, Sutherland EW, Liddle GW. Kinetic parameters and renal clearances of plasma adenosine 3′,5′-monophosphate and guanosine 3′,5′-monophosphate in man. J Clin Invest 1970; 49: 2222-2236.
24. Usberti M, Gargiulo A, Comberti E, Campisi S, Poiesi C, Brognoli M, Doregatti C, Rondina M, Zaneboni A, Ghielmi S. Effect of exogenous Prostaglandin E2 on plasma antidiuretic hormone in normal man. Am J Nephrol 1989; 9: 285-290.
25. Frölich JC, Wilson TW, Sweetman BJ, Smigel M, Nies AS, Carr K, Watson JT, Oates JA. Urinary prostaglandins. Identification and origin. J Clin Invest 1975; 55: 763-770.
26. Dunn MJ. Renal prostaglandins. In: Dunn MJ, ed. Renal Endocrinology. Baltimore: Williams and Wilkins, 1983: 1-74.
27. Arroyo V, Clària J, Saló J, Jeménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Seminars in Liver Disease 1994; 14: 44-58.
28. Arisz L, Donker AJM, Brentjens JRH, van der Hem GK. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976; 199: 121-125.
29. Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: Modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979; 48: 895-900.
30. Mirouze D, Zipser RD, Reynolds TB. Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 1983; 3: 50-55.
31. Pérez-Ayuso RM, Arroyo V, Camps J, Rimula A, Gaya J, Costa J, Rivera F, Rodés J. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26: 72-80.
32. Garnett ES, Webber CE. Changes in blood-volume produced by treatment in the nephrotic syndrome. Lancet 1967 No 2: 798-799
33. Bernardi M, Trevisani F, Santini C, De Palma R, Gasbarrini G. Aldosterone related blood volume expansion in cirrhosis before and during the early phase of ascites formation. Gut 1983; 24: 761-766.
34. Olmer M, Berland Y, Purgus R, Schultz G. Determination of blood volume in nephrotic patients. Am J Nephrol 1989; 9: 211-4.
35. Koomans HA, Braam B, Geers AB, Roos JC, Dorhout Mees EJ. The importance of plasma protein for blood volume and blood pressure homeostasis. Kidney Int 1986; 30: 730-35.
36. Geers AB, Koomans HA, Roos JC, Boer P, Dorhout Mees EJ. Functional relationships in the nephrotic syndrome. Kidney Int 1984; 26: 324-330.
37. Palmer BF. Southwestern internal medicine conference: Nephrotic edema-Pathogenesis and treatment. Am J Med Sci 1993; 306: 53-67.
38. Hadengue A, Moreau R, Gaudin C, Bacq Y, Champigneulle B, Lebrec D. Total effective vascular compliance in patients with cirrhosis: A study of the response to acute blood volume expansion. Hepatology 1992; 15: 809-815.
39. Koomans HA, Geers AB, Boer P, Roos JC, Dorhout Mees EJ. A study on the distribution of body fluids after rapid saline expansion in normal subjects and in patients with renal insufficiency: preferential intravascular deposition in renal failure. Clin Sci 1983; 64: 153-160.
40. Liard JF. Haemodynamics and body fluid volumes in response to fluid loading in conscious dogs: non-excretory renal influences. Clin Sci Mol Med 1976; 51: 243-255.
41. Koomans HA, Boer WH, Dorhout Mees EJ. Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int 1989; 36: 2-12.
42. Standard Techniques for the measurement of red-cell and plasma volume. A report by the International Committee for Standardization in Hematology (ICSH): Panel on diagnostic applications of radioisotopes in haematology. British J Haematol 1973; 25: 801-818.
43. Bauer JH, Willis LR, Burt RW, Grim CE. Volume studies. II. Simultaneous determination of plasma volume, red cell mass, extracellular fluid, and total body water before and after volume expansion in dog and man. J Lab Clin Med 1975; 86: 1009-1017.
44. Hansen J, Rønnov-Jessen V. Whole body hematocrit: Large vessel hematocrit ratio in hypertension. Acta Med Scand 1968; 183: 17-24.
45. Geers AB, Koomans HA, Boer P, Dorhout Mees EJ. Plasma and blood volumes in patients with the nephrotic syndrome. Nephron 1984; 38: 170-173.
46. Henriksen JH. Protein-kinetic and haemodynamic studies in patients with liver cirrhosis. Evidence of a lymph-imbalance theory of ascites formation. Clin Physiol 1981; 1: 565-578.
47. Solomon LR, Atherton JC, Bobinski H, Green R. Effect of dietary sodium chloride and posture on plasma immunoreactive atrial natriuretic peptide concentrations in man. Clin Sci 1987; 72: 201-208.
48. 2 using an antibody with high specificity and a sephadex LH-20 microcolumn for the separation of prostaglandins. Prostaglandins 1976; 11: 399-420.
49. Sørensen SS. Radio-immunoassay of endothelin in human plasma. Scand J Clin Lab Invest 1991; 51: 615-623.
50. Kappelgaard AM, Damkjær-Nielsen M, Giese J. Measurement of angiotensin II in human plasma: technical modification and practical experience. Clin Chim Acta 1976; 67: 299-306.
51. Rask-Madsen J, Bruusgaard A, Munck O, Nielsen MD, Worning H. The significance of bile acids and aldosterone for the electrical hyperpolarization of human rectum in obese patients treated with intestinal by-pass operation. Scand J Gastroenterol 1974; 9: 417-426.
52. Pedersen EB, Danielsen H, Spencer ES. Effect of endapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension. Eur J Clin Pharmacol 1984; 26: 543-547.
53. Hartter E, Woloszczuk W. Radioimmunological determination of arginine vasopressin and human atrial natriuretic peptide after simultaneous extraction from plasma. J Clin Chem Clin Biochem 1986; 24: 559-563.
54. de Jong PE, Anderson S, de Zeeuw D. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: Will such treatment also help to improve renal function outcome. J Am Soc Nephrol 1993; 3: 1333-1341.
55. Mogensen CE, Sølling K, Vittinghus E. Studies on mechanisms of proteinuria using amino-acid-induced inhibition of tubular reabsorption in normal and diabetic man. Contr Nephrol (Karger, Basel) 1981; 26: 50-65.
56. Viberti GC, Mogensen CE, Keen H, Jacobsen FK, Jarrett RJ, Christensen CK. Urinary excretion of albumin in normal man: the effect of water loading. Scand J Clin Lab Invest 1982; 42: 147-151.
57. Miles DW, Mogensen CE, Gundersen HJG. Radioimmunoassay for urinary albumin using a single antibody. Scand J Clin Lab Invest 1970; 26: 5-11.
58. Mogensen CE. Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. Scand J Clin Lab Invest 1971; 28: 91-100.
59. Skov PE, Hansen HE. The functional pattern in patients with renal disease. Acta Med Scand 1974; 196: 378-392.
60. Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, Alberino F, Gatta A. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154: 201-205.
61. Janssen WMT, de Zeeuw D, van der Hem GK, de Jong PE. Atrial natriuretic peptide-induced decreases in renal blood flow in man: implications for the natriuretic mechanism. Clin Sci 1989; 77: 55-60.
62. Boer WH, Koomans HA, Dorhout Mees EJ. Renal lithium handling during water loading and subsequent d-DAVP-induced anti-diuresis. Eur J Clin Invest 1988; 18: 273-278.
63. Shore AC, Markandu ND, Sagnella GA, Singer DRJ, Forsling ML, Buckley MG, Sugden AL, MacGregor GA. Endocrine and renal response to water loading and water restriction in normal man. Clin Sci 1988; 75: 171-177.
64. Kimura T, Abe K, Ota K, Omata K, Shoji M, Kudo K, Matsui K, Inoue M, Yasujima M, Yoshinaga K. Effects of acute water load, hypertonic saline infusion, and furosemide administration on atrial natriuretic peptide and vasopressin release in humans. J Clin Endocrinol Metab 1986; 62: 1003-1010.
65. Thomsen K. Lithium clearance: A new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 1984; 37: 217-223.
66. Thomsen K, Schou M, Vestergaard P. Distinction between proximal and distal regulations of sodium and potassium excretion in humans. Clin Nephrol 1988; 29: 12-18.
67. Hayslett JP, Kashgarian M. A micropuncture study of the renal handling of lithium. Pflügers Arch 1979; 380: 159-163.
68. Leyssac PP, Holstein-Ratlou N-H, Skøtt P, Alfrey AC. A micropuncture study of proximal tubular transport of lithium during osmotic diuresis. Am J Physiol 1990; 258: F1090-F1095.
69. Shirley DG, Walter SJ, Sampson B. A micropuncture study of renal lithium reabsorption: effects of amiloride and furosemide. Am J Physiol 1992; 263: F1128-F1133.
70. Atherton JC, Green R, Hughes S, Mcfall V, Sharples JA, Solomon LR, Wilson L. Lithium clearance in man: effects of dietary salt intake, acute changes in extracellular fluid volume, amiloride and frusemide. Clin Sci 1987; 73: 645-651.
71. Bruun NE, Skøtt P, Lønborg-Jensen H, Giese J. Unchanged lithium clearance during acute amiloride treatment in sodium-depleted man. Scand J Clin Lab Invest 1989; 49: 259-263.
72. Boer WH, Koomans HA, Dorhout Mees EJ, Gaillard CA, Rabelink AJ. Lithium clearance during variations in sodium intake in man: effects of sodium restriction and amiloride. Eur J Clin Invest 1988; 18: 279-283.
73. Angeli P, De Bei E, Dalla Pria M, Caregaro L, Ceolotto G, Albino G, Gatta A. Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. Hepatology 1992; 15: 651-654.
74. Shirley DG, Walter SJ. Current status of the lithium clearance method for the assessment of renal proximal tubular function. Lithium 1993; 4: 25-31.
75. Shirley DG, Singer DRJ, Sagnella GA, Buckley MG, Miller MA, Markandu ND, MacGregor GA. Effect of a single test dose of lithium carbonate on sodium and potassium excretion in man. Clin Sci 1991; 81: 59-63.
76. Eidemak I, Strandgaard S, Leyssac PP, Christensen P. Endogenous versus exogenous lithium clearance. Nephrol Dial Transplant 1994; 9: 447A.
77. Leach C. Introduction to statistics. A nonparametric approach for the social sciences. Chishester, New York, Brisbane, Toronto: John Wiley and sons, 1979.
78. Sjöström PA, Odlind BG, Beermann BA, Karlberg BE. Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome. Eur J Clin Pharmacol 1989; 37: 173-180.
79. Danielsen H, Pedersen EB, Christensen NJ. Relationship of angiotensin II, aldosterone, arginine vasopressin, adrenaline and noradrenaline in plasma, blood and extracellular volumes to blood pressure in chronic glomerulonephritis. Eur J Clin Invest 1986; 16: 85-90.
80. Brown EA, Markandu ND, Roulston JE, Jones BE, Squires M, MacGregor GA. Is the renin-angiotensin-aldosterone system involved in the sodium retention in the nephrotic syndrome. Nephron 1982; 32: 102-107.
81. Brod J, Bahlmann J, Cachovan M, Pretschner P. Development of hypertension in renal disease. Clin Sci 1983; 64: 141-152.
82. Valvo E, Gammaro L, Bedogna V, Giorgetti PG, Tonon M, Pazetta GO, Lupo A, Luschiaro C, Tessitore N, Oldrizzi L, Rugiu C, Ortalda V, Maschio G. Hypertension in primary immunoglobulin A nephropathy (Berger's disease): Hemodynamic alterations and mechanisms. Nephron 1987; 45: 219-223.
83. Tulassay T, Rascher W, Lang RE, Seyberth HW, Schärer K. Atrial natriuretic peptide and other vasoactive hormones in nephrotic syndrome. Kidney Int 1987; 31: 1391-1395.
84. Johnston PA, Davison AM. Hypertension in adults with idiopathic glomerulonephritis and normal serum creatinine. A report from the MRC glomerulonephritis registry. Nephrol Dial Transplant 1993; 8: 20-24.
85. Almeida FA, Suzuki M, Maack T. Atrial natriuretic factor increases hematocrit and decreases plasma volume in nephrectomized rats. Life Sci 1986; 39: 1193-1199.
86. Jespersen B, Pedersen EB. Increased plasma levels of atrial natriuretic peptide in patients with chronic renal failure: effect of noradrenaline infusion. Nephrol Dial Transplant 1988; 3: 762-767.
87. Dussaule JC, Michel C, Peraldi MN, Lecomte JM, Gros C, Mignon F, Ardaillou R. Inhibition of neutral endopeptidase stimulates renal sodium excretion in patients with chronic renal failure. Clin Sci 1993; 84: 31-39.
88. Ljutic D, Rumboldt Z. The influence of the atrial natriuretic factor on venous tone in man. Int J Clin Pharm Res 1989; X(4): 255-260.
89. Huxley VH, Tucker VL, Verburg KM, Freeman RH. Increased capillary hydraulic conductivity induced by atrial natriuretic peptide. Circ Res 1987; 60: 304-307.
90. Pedersen EB, Danielsen H, Sørensen SS, Jespersen B. Renal water excretion before and after remission of nephrotic syndrome: relationship between free water clearance and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading. Clin Sci 1986; 71: 97-104.
91. Shapiro MD, Nicholls KM, Groves BM, Schrier RW. Role of glomerular filtration rate in the impaired sodium and water excretion of patients with the nephrotic syndrome. Am J Kidney Dis 1986; 8: 81-87.
92. Dorhout Mees EJ, Roos JC, Boer P, You OH, Simatupang TA. Observations on edema formation in the nephrotic syndrome in adults with minimal lesions. Am J Med 1979; 67: 378-384.
93. Scheurlen PG, Klaus D. Flüssigkeitshaushalt und volumenregulation bei extremen serumalbuminmangel (analbuminämie). Klinische Wochenschrift 1960; 38: 123-126.
94. Brown EA, Markandu N, Sagnella GA, Jones BE, MacGregor GA. Sodium retention in nephrotic syndrome is due to an intrarenal defect: Evidence from steroid-induced remission. Nephron 1985; 39: 290-295.
95. Garin EH, Paul RV. Atrial natriuretic factor in idiopathic minimal-lesion nephrotic syndrome. Child Nephrol Urol 1990; 10: 65-67.
96. Pedersen EB, Danielsen H, Eiskjær H, Jespersen B, Sørensen SS. Increased atrial natriuretic peptide in the nephrotic syndrome. Relationship to renal function and the renin-angiotensin-aldosterone system. Scand J Clin Lab Invest 1988; 48: 141-147.
97. Peterson C, Madsen B, Perlman A, Chan AYM, Myers BD. Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans. Kidney Int 1988; 34: 825-831.
98. Firth JD, Ledingham JGG. Effect of natriuretic agents, vasoactive agents and of the inhibition of metabolism on sodium handling in the isolated perfused kidney of the nephrotic rat. Clin Sci 1990; 79: 559-574.
99. Ting RH, Kristal B, Myers BD. The biophysical basis of hypofiltration in nephrotic humans with membranous nephropathy. Kidney Int 1994; 45: 390-397.
100. Lauridsen IN, Jespersen B, Thomsen K, Pedersen EB. Abnormal glomerular and tubular response to intravenous frusemide in patients with chronic glomerulonephritis, Nephrol Dial Transplant 1991; 6: 466-475.
101. Sechi LA, Palomba D, Bartoli E. Acute effects of furosemide on blood presssure in functionally anephric, volume-expanded rats. Am J Nephrol 1993; 13: 94-99
102. Struyker-Boudier HAJ, Smits JFM, Kleinjans JCS, van Essen H. Hemodynamic actions of diuretic agents. Clin Exp Hyper Theory and Practice 1983; A5(2): 209-223.
103. Abe K, Yasujima M, Chiba S, Irokawa N, Ito T, Yoshinaga K. Effect of furosemide on urinary excretion of prostaglandin E in normal volunteers and patients with essential hypertension. Prostaglandins 1977; 14: 513-521.
104. Williamson HE, Bourland WA, Marchand GR, Farley DB, van Orden DE. Furosemide induced release of prostaglandin E to increase renal blood flow. Proc Soc Exp Biol Med 1975; 150: 104-106.
105. Smith DE, Hyneck ML, Berardi RR, Port FK. Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients. J Pharmaceut Sci 1985; 74: 603-607.
106. Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, Branch RA. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uraemia. Clin Pharmacol Ther 1978; 24: 199-207.
107. Kirchner KA, Voelker JR, Craig Brater D. Intratubular albumin blunts the response to furosemide - A mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 1990; 252: 1097-1101.
108. Kirchner KA, Voelker JR, Craig Brater D. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int 1991; 40: 418-424.
109. Voelker JR, Jameson DM, Craig Brater D. In vitro evidence that urine composition affects the fraction of active furosemide in the nephrotic syndrome. J Pharmacol Exp Ther 1989; 250: 772-778.
110. Biollaz J, Bidiville J, Diézi J, Waeber B, Nussberger J, Brunner-Ferber F, Gomez HJ, Brunner HR. Site of the action of a synthetic atrial natriuretic peptide evaluated in humans. Kidney Int 1987; 32: 537-546.
111. Van de Stolpe A, Jamison RL. Micropuncture study of the effect of ANP on the papillary collecting duct in the rat. Am J Physiol 1988; 254: F477-F483.
112. Fried TA, McCoy RN, Osgood RW, Stein JH. Effect of atriopeptin II on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus. Am J Physiol 1986; 250: F1119-F1122.
113. Perico N, Delaini F, Lupini C, Benigni A, Galbusera M, Boccardo P, Remuzzi G. Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. Kidney Int 1989; 36: 57-64.
114. Eiskjær H, Jensen JD, Jespersen B, Sørensen SS, Pedersen EB. Abnormal tubular handling of sodium and water induced by atrial natriuretic peptide in essential hypertension. J Int Med 1991; 230: 37-48.
115. Kim JK, Summer SN, Durr J, Schrier RW. Enzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons. Kidney Int 1989; 35: 799-805.
116. Rabelink TJ, Koomans HA, van de Stolpe A, Bijlsma JA, Dorhout Mees EJ. Effects of atrial natriuretic peptide on distal tubule function in humans. Kidney Int 1990; 37: 996-1001.
117. Valentin J-P, Qui C, Muldowney WP, Ying W-Z, Gardner DG, Humphreys MH. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 1992; 90: 1302-1312.
118. Woolf AS, Lyon TL, Hoffbrand BI, Cohen SL, Moult PJA. Effects of physiological infusion of atrial natriuretic factor on healthy subjects and patients with the nephrotic syndrome. Nephron 1989; 52: 244-250.
119. Zhang PL, Mackenzie HS, Troy JL, Brenner BM. Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats. J Am Soc Nephrol 1994; 4: 1564-1570.
120. Bernard DB. Extrarenal complications of the nephrotic syndrome. Kidney Int 1988; 33: 1184-1202.
121. Tiggeler RGWL, Koene RAP, Wijdeveld PGAB. Inhibition of frusemide-induced natriuresis by indomethacin in patients with the nephrotic syndrome. Clin Sci Mol Med 1977; 52: 149-151.
122. Usberti M, Di Minno G, Ungaro B, Cianciaruso B, Federico S, Ardillo G, Gargiulo A, Martucci F, Pannain M, Cerbone AM, Conte G, Pecoraro C, Andreucci VE. Angiotensin II inhibition with captopril on plasma ADH, PG synthesis, and renal function in humans. Am J Physiol 1986; 250: F986-F990.
123. Podjarny E, Bernheim JL, Pomeranz A, Rathaus M, Pomeranz M, Green J, Bernheim J. Effect of timing of antihypertensive therapy on glomerular injury: comparison between captopril and diltiazem. Nephrol Dial Transplant 1993; 8: 501-506.
124. Kamper A-L, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 1992; 5: 423-430.
125. Brown EA, Sagnella GA, Jones BE, Markandu ND, Squires M, MacGregor GA. Evidence that some mechanism other than the renin system causes sodium retention in nephrotic syndrome. Lancet 1982 No. 2: 1237-1239.
126. Rosenberg ME, Swanson JE, Thomas BL, Hostetter TH. Glomerular and hormonal responses to dietary protein intake in human renal disease. Am J Physiol 1987; 253: F1083-F1090.
127. Golbetz H, Black V, Shemesh O, Myers BD. Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans. Am J Physiol 1989; 256: F44-F52.
128. Rector WG, Adair O, Hossack KF, Rainguet S. Atrial volume in cirrhosis: Relationship to blood volume and plasma concentration of atrial natriuretic factor. Gastroenterology 1990; 99: 766-770.
129. Fernández-Rodriguez CM, Prieto J, Zozaya JM, Quiroga J, Guitian R. Arteriovenous shunting, hemodynamic changes, and renal sodium retention in liver cirrhosis. Gastroenterology 1993; 104: 1139-1145.
130. Lieberman FL, Reynold TB: Plasma volume in cirrhosis of the liver, its relation to portal hypertension, ascites and renal failure. J Clin Invest 1967; 46: 1297-1308.
131. Larsen OA, Winkler K, Tygstrup N. "Extra" plasma in the liver calculated from the hepatic hematocrit in patients with portacaval anastomosis. Clin Sci 1963; 25: 357-362.
132. Levy M, Wexler MJ. Hepatic denervation alters first-phase urinary sodium excretion in dogs with cirrhosis. Am J Physiol 1987; 253: F664-671.
133. Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. Gut 1974; 15: 99-101.
134. Moreau R, Hadengue A, Pussard E, Soubrane O, Sogni P, Gaudin C, Lebrec D. Relationship between plasma atrial natriuretic peptide concentrations and hemodynamics and hematocrit in patients with cirrhosis. Hepatology 1991; 14: 1035-1039.
135. Warner LC, Campbell PJ, Morali GA, Logan AG, Skorecki KL, Blendis LM. The response of atrial natriuretic factor and sodium excretion to dietary sodium challenges in patients with chronic liver disease. Hepatology 1990; 12: 460-466.
136. Henriksen JH, Ring-Larsen H. Ascites formation in liver cirrhosis: The how and the why. Dig Dis 1990; 8: 152-162.
137. Maroto A, Ginès P, Arroyo V, Ginès A, Saló J, Clària J, Jiménez W, Bru C, Rivera F, Rodés J. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17: 788-793.
138. Sato S, Ohnishi K, Sugita S, Okuda K. Splenic artery and superior mesenteric artery blood flow: nonsurgical Doppler US measurement in healthy subjects and patients with chronic liver disease. Radiology 1987; 164: 347-352.
139. Silva G, Nasava M, Bosch J, Chesta J, Pizcueta MP, Cassamitjana R, Rivera F, Rodés J. Hemodynamic effects of glucagon in portal hypertension. Hepatology 1990; 11: 668-673.
140. Clària J, Jiménez W, Ros J, Asbert M, Castro A, Arroyo V, Rivera F, Rodés J. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: Role of endogenous nitric oxide. Hepatology 1992; 15: 343-349.
141. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-778.
142. Levy M. Hepatorenal syndrome. Kidney Int 1993; 43: 737-753.
143. Henriksen JH, Ring-Larsen H. Hepatorenal disorders: Role of the sympathetic nervous system. Seminars in Liver Disease 1994; 14: 35-43.
144. Henriksen JH, Bendtsen F, Sørensen TIA, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97: 1506-1513.
145. Morali GA, Floras JS, Legault L, Tobe S, Skorecki KL, Blendis LM. Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. Am J Med 1991; 91: 383-392.
146. Ring-Larsen H, Hesse B, Stigsby B. Effect of portal-systemic anastomosis on renal haemodynamics in cirrhosis. Gut 1976; 17: 856-860.
147. Blendis LM, Sole MJ, Campbell P, Lossing AG, Greig PD, Taylor BR, Langer B. The effect of peritoneovenous shunting on catecholamine metabolism in patients with hepatic ascites. Hepatology 1987; 7: 143-148.
148. Wong F, Liu P, Tobe S, Morali G, Blendis L. Central blood volume in cirrhosis: Measurement with radionuclide angiography. Hepatology 1994; 19: 312-321.
149. Henriksen JH, Møller S, Bendtsen F, Ring-Larsen H, Stokholm KH, Møgelvang J, Sørensen TIA, Gerbes AL. Assessment of central blood volume in cirrhosis by radionuclide angiography: What does it really mean (letter). Hepatology 1994; 20: 1652-1656.
150. Epstein M, Levinson R, Sancho J, Haber E, Re R. Characterization of the renin-aldosterone system in decompensated cirrhosis. Circ Res 1977; 41: 818-829.
151. Asbert M, Ginès A, Ginès P, Jiménez W, Clària J, Saló J, Arroyo V, Rivera F, Rodés J. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104: 1485-1491.
152. Jiménez W, Gutkowska J, Ginés P, Arroyo V, Rivera F, Rodés J. Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites. Hepatology 1991; 14: 601-607.
153. Ginès P, Jiménez W, Arroyo V, Navasa M, López C, Titó L, Serra A, Bosch J, Sanz G, Rivera F, Rodés J. Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology 1988; 8: 636-642.
154. Bonkovsky HL, Hartle DK, Mellen BG, Kutner M, Galambos JT. Plasma concentrations of immunoreactive atrial natriuretic peptide in hospitalized cirrhotic and noncirrhotic patients: Evidence for a role of deficient atrial natriuretic peptide in pathogenesis of cirrhotic ascites. Am J Gastroenterol 1988; 83: 531-535.
155. Gerbes AL, Wernze H, Arendt RM, Riedel A, Sauerbruch T, Paumgartner G. Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. Hepatology 1989; 9: 417-422.
156. Henriksen JH, Bendtsen F, Schütten HJ, Warberg J. Hepatic-intestinal disposal of endogenous human alpha atrial natriuretic factor 99-126 in patients with cirrhosis. Am J Gastroenterol 1990; 85: 1155-1159.
157. Vesely DL, Preston R, Winters CJ, Rico DM, Sallman AL, Epstein M. Increased release of the N-terminal and C-terminal portions of the atrial natriuretic factor prohormone during immersion-induced central hypervolemia in cirrhotic humans. Am J Nephrol 1991; 11: 207-216.
158. Lewis FW, Adair O, Rector WG. Arterial vasodilation is not the cause of increased cardiac output in cirrhosis. Gastroenterology 1992; 102: 1024-1029.
159. Møller S, Søndergaard L, Møgelvang J, Henriksen O, Henriksen JH. Decreased right heart blood volume determined by magnetic resonance imaging: Evidence of central underfilling in cirrhosis. Hepatology 1995; in press.
160. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 1774-1778.
161. Uchihara M, Izumi N, Sato C, Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 1992; 16: 95-99.
162. Gerbes AL, Møller S, Gülberg V, Henriksen JH. Endothelin-1 and-3 plasma concentrations in patients with cirrhosis. Role of splanchnic and renal passage and liver function. Hepatology 1995; 21: 735-739.
163. Veglio F, Pinna G, Melchio R, Rabbia F, Panarelli M, Gagliardi B, Chiandussi L. Plasma endothelin levels in cirrhotic subjects. J Hepatol 1992; 15: 85-87.
164. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci 1993; 84: 485-500.
165. Sørensen SS, Madsen JK, Pedersen EB. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol 1994; 266: F411-418.
166. Cozza EN, Gomez-Sanchez CE, Foecking MF, Chiou S. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Invest 1989; 84: 1032-1035.
167. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders: Role of the renin-angiotensin-aldosterone system. Seminars in liver disease 1994; 14: 23-34.
168. Gluud C. Serum testosteron concentrations in men with alcoholic cirrhosis: Background for variation. Metabolism 1987; 36: 373-378.
169. 2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome). J Hepatol 1986; 3: 111-117.
170. Govindarajan S, Nast CC, Smith WL, Kovle MA, Daskalopoulos G, Zipser RD. Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome. Hepatology 1987; 7: 654-659.
171. Leehey DJ. Dissociation between pressor sensitivity in vivo and contractile reactivity in vitro to angiotensin II in rats with experimental cirrhosis. Clin Sci 1993; 84: 525-529.
172. Braillon A, Gaudin C, Poo JL, Moreau R, Debaene B, Lebrec D. Plasma catecholamine concentrations are a reliable index of sympathetic vascular tone in patients with cirrhosis. Hepatology 1992; 15: 58-62.
173. Henriksen JH, Christensen NJ, Ring-Larsen H. Noradrenaline and adrenaline concentrations in various vascular beds in patients with cirrhosis. Relation to Haemodynamics. Clin Physiol 1981; 1: 293-304.
174. Moss NG. Renal function and renal afferent and efferent nerve activity. Am J Physiol 1982; 243: F425-433.
175. Simón M-A, Díez J, Prieto J. Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis. Gastroenterology 1991; 101: 1354-1360.
176. Leslie SH, Johnston B, Ralli EP. Renal function as a factor in fluid retention in patients with cirrhosis of the liver. J Clin Invest 1951; 30: 1200-1207.
177. Wong F, Massie D, Colman J, Dudley F. Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. Gastroenterology 1993; 104: 884-889.
178. Wong F, Massie D, Hsu P, Dudley F. Renal response to a saline load in well-compensated alcoholic cirrhosis. Hepatology 1994; 20: 873-881.
179. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 1993; 43: 1306-1312.
180. Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology 1993; 104: 869-876.
181. Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Renal vasoconstriction in cirrhosis evaluated by Duplex Doppler Ultrasonography. Hepatology 1993; 17: 219-224.
182. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977; 37: 635-642.
183. Kew MC, Varma RR, Williams HS, Brunt PW, Hourigan KJ, Sherlock S. Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971; 49: 504-509.
184. Moreau R, Gaudin C, Hadengue A, Braillon A, Roulot D, Bacq Y, Lebrec D. Renal hemodynamics in patients with cirrhosis: relationship with ascites and liver failure. Nephron 1993; 65: 359-363.
185. Moreau R, Soubrane O, Sogni P, Hadengue A, Gaudin C, Lin HC, Pussard E, Nahoul K, Lebrec D. Hemodynamic, neurohumorel, and metabolic responses to amino acid infusion in patients with cirrhosis. Gastroenterology 1992; 103: 601-608.
186. Planas R, Arroyo V, Rimola A, Pérez-Ayuso RM, Rodés J. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983; 84: 247-252.
187. Badalamenti S, Ginés P, Arroyo V, Llach J, Piera C, Rimola A, Jiménez W, Gaya J, Casamitjana R, Rivera F, Rodés J. Effects of intravenous amino acid infusion and dietary proteins on kidney function in cirrosis. Hepatology 1990; 11: 379-386.
188. Hattori K, Yauchi T, Minato Y, Hasumura Y, Takeuchi J, Shigai T. A lithium clearance study of sodium reabsorption at the proximal tubule in liver cirrhosis with ascites. Gastroenterologia Japonica 1989; 24: 535-539.
189. Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in non-azotemic cirrhotic patients. Hepatology 1991; 14: 231-236.
190. Eiskjær H, Sørensen SS, Danielsen H, Pedersen EB. Glomerular and tubular antinatriuretic actions of low-dose angiotensin II infusion in man. J Hypertens 1992; 10: 1033-1040.
191. Madsen M, Pedersen EB, Danielsen H, Jensen LS, Sørensen SS. Impaired renal water excretion in early hepatic cirrhosis. Scand J Gastroenterology 1986; 21: 749-755.
192. Papper S, Rosenbaum JD. Abnormalities in the excretion of water and sodium in "compensated" cirrhosis of the liver. J Lab Clin Med 1952; 40: 523-530.
193. Cosby RL, Yee B, Schrier RW. New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989; 15: 261-266.
194. Henriksen JH, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993; 18: 688-695.
195. Hendrickse MT, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am J Gastroenterol 1994; 89: 750-757.
196. Kirschenbaum MA, Serros ER. Effects of alterations in urine flow rate on prostaglandin E excretion in conscious dogs. Am J Physiol 1980; 238: F107-F111.
197. Cereda JM, Roulot D, Braillon A, Moreau R, Koshy A, Lebrec D. Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. J Hepatol 1989; 9: 246-251.
198. Salerno F, Badalamenti S, Moser P, Lorenzano E, Incerti P, Dioguardi N. Atrial natriuretic factor in cirrhotic patients with tense ascites. Gastroenterology 1990; 98: 1063-1070.
199. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJC. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 1973; 288: 1087-1090.
200. Bourland WA, Day DK, Williamson HE. The role of the kidney in the early nondiuretic action of furosemide to reduce elevated left atrial pressure in the hypervolemic dog. J Pharmacol Exp Therapeut 1977; 202: 221-229.
201. Antillon M, Cominelli F, Reynolds TB, Zipser RD. Comparative acute effects of diflunisal and indomethacin on renal function in patients with cirrhosis and ascites. Am J Gastroenterol 1989; 84: 153-155.
202. Quiroga J, Zozaya JM, Labarga P, Rodríguez-Ortigosa CM, Milazzo A, Prieto J. Renal prostacyclin influences renal function in non-azotemic cirrhotic patients treated with furosemide. J Hepatol 1991; 12: 170-175.
203. Karlén I, Rane S, Aperia A. Tubular response to hormones is blunted in weanling rats. Acta Physiol Scand 1990; 138: 443-449.
204. Lenz K, Hörtnagl H, Druml W, Grimm G, Laggner A. Schneeweisz B, Kleinberger G. Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut 1989; 30: 90-96.
205. Pinzani M, Laffi G, Meacci E, La Villa G, Cominelli F, Gentilini P. Intrarenal thromboxane A2 generation reduces the furosemide-induced sodium and water diuresis in cirrhosis with ascites. Gastroenterology 1988; 95: 1081-1087.
206. Dussaule J-C, Grangé J-D, Wolf J-P. Lecomte A-M, Gros C, Schwartz J-C. Bodin F, Ardaillou R. Effect of Sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J Clin Endocrinol Metab 1991; 72: 653-659.
207. Salerno F, Badalamenti S, Incerti P, Capozza L, Mainardi L. Renal response to atrial natriuretic peptide in patients with advanced liver cirrhosis. Hepatology 1988; 8: 21-26.
208. Beutler JJ, Koomans HA, Rabelink TJ, Gaillard CA, Van Hattum J, Boer P, Dorhout Mees EJ. Blunted natriuretic response and low blood pressure after atrial natriuretic factor in early cirrhosis. Hepatology 1989; 10: 148-153.
209. Ferrier C, Beretta-Piccoli C, Weidmann P, Gnädinger MP, Shaw S, Suchecka-Rachon K, Saxenhofer H. Hypotension and renal impairment during infusion of atrial natriuretic factor in liver cirrhosis with ascites. Am J Nephol 1989; 9: 291-299.
210. Laffi G, Pinzani M, Meacci E, La Villa G, Renzi D, Baldi E, Cominelli F, Marra F, Gentilini P. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. Gastroenterology 1989; 96: 167-177.
211. Petrillo A, Scherrer U, Gonvers JJ, Nussberger J, Marder H, de Vane P, Waeber B, Hofstetter JR, Brunner HR. Atrial natriuretic peptide administrated as intravenous infusion or bolus injection to patients with liver cirrhosis and ascites. J Cardiovasc Pharmacol 1988; 12: 279-285.
212. Eiskjær H, Pedersen EB. Dose-response study of atrial natriuretic peptide bolus injection in healthy man. Eur J Clin Invest 1993; 23: 37-45.
213. Ginès P, Titó, L, Arroyo V, Llach J, Salmerön JM, Ginès A, Jiménez W, Badalamenti S, Rivera F, Rodés J. Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure. Gastroenterology 1992; 102: 280-286.
214. Gerbes AL, Kollenda MC, Vollmar AM, Reichen J, Vakil N, Scarborough RM. Altered density of glomerular binding sites for atrial natriuretic factor in bile duct-ligated rats with ascites. Hepatology 1991; 13: 562-566.
215. Salmerón JM, del Arbol LR, Ginès A, García-Pagan JC, Ginès P, Feu F, Claria J, Rivera F, Bosch J, Arroyo V, Rodés J. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 1993; 17: 800-806.
216. Saijonmaa O, Ristimäki A, Fyhrquist F. Atrial natriuretic peptide, nitroglycerine and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells. Biochem Biophys Res Commun 1990; 173: 514-520.
217. Legault L, Warner LC, Leung WM, Logan AG, Blendis LM, Skorecki KL. Assessment of atrial natriuretic peptide resistance in cirrhosis with head-out water immersion and atrial natriuretic peptide infusion. Can J Physiol Pharmacol 1993; 71: 157-164.
218. Angeli P, Jiménez W, Arroyo V, Mackenzie HS, Zhang PL, Clària J, Rivera F, Brenner BM, Rodés J. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994; 20: 948-954.
219. Brunkchorst R, Wrenger E, Kühn K, Schmidt FW, Koch K. Effekte einer captopriltherapie auf die natrium-und wasserausscheidung bei patienten mit leberzirrhose und aszites. Klin Wochenschr 1989; 67: 774-783.
220. Van Vliet AA, Hackeng WH, Donker AJM; Meuwissen SGM. Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis. J Hepatol 1992; 15: 40-47.
221. Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, Raggi VC, Foschi M, Marra F, Pinzani M, Buzzelli G, Laffi G. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993; 104: 588-594.
222. Morali GA, Tobe SW, Skorecki KL, Blendis LM. Refractory ascites: modulation of atrial natriuretic factor unresponsiveness by mannitol. Hepatology 1992; 16: 42-48.
223. Koepke JP, Jones S, Dibona GF. Renal nerves mediate blunted natriuresis to atrial natriuretic peptide in cirrhotic rats. Am J Physiol 1987; 252: R1019-R1023.
224. Bernardi M, de Palma R, Trevisani F, Tamè MR, Ciancaglini GC, Pesa O, Ligabue A, Baraldini M, Gasbarrini G. Renal function and effective beta-blockade in cirrhosis with ascites. Relationship with baseline sympathoadrenergic tone. J Hepatol 1989; 8: 279-286.
225. Hesse IFA, Johns EJ. The subtype of alpha-adrenoceptor involved in the neural control of renal tubular sodium reabsorption in the rabbit. J Physiol 1984; 352: 527-538.
226. O'Connell JE, Jardine AG, Davies DL, McQueen J. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clin Sci 1993; 85: 19-26.
227. Bennett W, Keeffe E, Melnyk C, Mahler D, Rösch J, Porter GA. Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975; 135: 964-971.
228. Salerno F, Incerti P, Badalamenti S, Lorenzano E, Graziani G, Morganti A, Ghirardi P. Renal and humoral effects of ibopamne, a dopamine agonist, in patients with liver cirrhosis. Arch Intern Med 1990; 150: 65-69.
229. 1 analogue) and albumin administration. J Hepatol 1990; 11: 153-158.
230. 2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993; 17: 220-226.
231. Melki TS, Foegh ML, Ramwell PW. Implication of thromboxane in frusemide diuresis in rats. Clin Sci 1986; 71: 647-650.
232. Zipser RD, Kronborg I, Rector W, Reynolds T, Daskalopoulos G. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. Gastroenterology 1984; 87: 1228-1232.
233. Chao Y, Wang S-S, Lee F-Y, Lin H-C, Lo G-H, Tsai Y-T, Lee S-D. Measurement of intravariceal pressure by fine needle direct puncture in hepatitis B surface antigen-positive cirrhotic patients: The effect of vasopressin. J Gastroenterol Hepatol 1993; 8: 157-160.
234. Tulassau Z, Tulassay T, Szathmáry M. Does somatostatin influence kidney function in cirrhosis? (letter) Gastroenterology 1993; 104: 1892-1893.
235. Ginès A, Salmerón JM, Ginès P, Jiménez W, Saló J, Piera C, Clària J, Rivera F, Arroyo V, Rodés J. Effects of somatostatin on renal function in cirrhosis. Gastroenterology 1992; 103: 1868-1874.
236. Wong F, Tobe S, Legault L, Logan AG, Skorecki K, Blendis LM. Refractory ascites in cirrhosis: roles of volume expanion and plasma atrial natriuretic factor level elevation. Hepatology 1993; 18: 519-528.
237. Bernardi M, di Marco C, Trevisani F, Fornalè L, Andreone P, Cursaro C, Baraldini M, Ligabue A, Tamè MR, Gasbarrini G. Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 1993; 105: 188-193.